Prestige Consumer Healthcare (NYSE:PBH) Rating Lowered to “Hold” at StockNews.com

Prestige Consumer Healthcare (NYSE:PBH) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

Several other equities analysts have also recently weighed in on the company. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research note on Monday, December 9th. DA Davidson reiterated a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $85.25.

Prestige Consumer Healthcare Trading Down 1.4 %

Shares of NYSE:PBH traded down $1.07 during mid-day trading on Monday, hitting $77.38. The stock had a trading volume of 143,387 shares, compared to its average volume of 251,466. The company’s 50 day moving average is $80.08 and its 200-day moving average is $73.71. Prestige Consumer Healthcare has a 12-month low of $57.95 and a 12-month high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The company has a market cap of $3.82 billion, a PE ratio of 18.83, a P/E/G ratio of 2.32 and a beta of 0.49.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to the consensus estimate of $282.09 million. During the same period in the previous year, the business earned $1.07 EPS. The company’s revenue was down .9% on a year-over-year basis. On average, sell-side analysts predict that Prestige Consumer Healthcare will post 4.44 EPS for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total transaction of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at $1,505,930. This represents a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock worth $3,187,300 over the last ninety days. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently modified their holdings of the company. Martingale Asset Management L P raised its holdings in Prestige Consumer Healthcare by 0.4% in the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company’s stock worth $2,666,000 after acquiring an additional 140 shares during the period. Horizon Kinetics Asset Management LLC increased its stake in shares of Prestige Consumer Healthcare by 4.8% in the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company’s stock worth $234,000 after purchasing an additional 150 shares during the period. Evergreen Capital Management LLC lifted its position in shares of Prestige Consumer Healthcare by 5.4% during the 2nd quarter. Evergreen Capital Management LLC now owns 3,143 shares of the company’s stock worth $216,000 after purchasing an additional 160 shares during the last quarter. OLD National Bancorp IN boosted its stake in Prestige Consumer Healthcare by 4.4% during the 3rd quarter. OLD National Bancorp IN now owns 3,974 shares of the company’s stock valued at $287,000 after purchasing an additional 168 shares during the period. Finally, Huntington National Bank boosted its stake in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after purchasing an additional 181 shares during the period. 99.95% of the stock is owned by institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.